Navigation Links
Ampio Awarded US and Canadian Patents that will Bolster the Commercialization of Optina™ for the treatment of Diabetic Macular Edema (DME)
Date:4/27/2012

GREENWOOD VILLAGE, Colo., April 27, 2012 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (Nasdaq: AMPE), a biopharmaceutical company conducting clinical trials on its three lead drugs (Ampion™, Optina™ and Zertane™), licensing distribution of these drugs and developing additional new drugs, today announced that it received notice of allowance of a patent from the US office of patents and trademarks for its DME drug Optina™. Ampio also received a notice of allowance of a similar patent from the Canadian Intellectual Property Office. These initial patents cover the North American territories and multiple additional patents for using Optina™ for the treatment of macular edema and diabetic retinopathy are pending worldwide.

According to Michael Macaluso, Ampio's CEO, "Optina™ is an ultra-low oral (capsule), not commercially available, dose of danazol for the treatment of DME. To our knowledge, no other oral drug to treat this condition exists and there is currently no drug approved by the FDA for this condition. The allowance of these patents in North America is an important step in the development and commercialization of this novel drug as they include multiple claims for the beneficial effects of ultra-low dose Optina™ on vascular hyperpermeability encountered in DME and other vascular leakage syndromes. These patents have an unusually long patent life that expires in 2030. In contrast, most drugs at this stage of development (just before a pivotal trial) have exhausted a large portion of their patent life. These patent claims provide especially strong protection because of the unexpected finding of efficacy only at the very low doses. Ampio is currently in discussions with potential partners to co-develop Optina™ for DME."

Dr. David Bar-Or, Chief Scientific Officer for Ampio, explained, "The mode of action of Optin
'/>"/>

SOURCE Ampio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ampio Strengthens Patent Protection for Lead Drug Ampion™
2. Ampio Announces Positive Preliminary Update on the Optina™ Clinical Trial to Treat Diabetic Macular Edema and Decision to Conclude the Study Ahead of Schedule
3. Champions Oncology Reports Fiscal 2012 Third Quarter Financial Results
4. Ampio Pharmaceuticals Reports Full-Year 2011 Financial Results and Milestone Highlights for 2011
5. Ampio Pharmaceuticals Schedules 2012 Outlook Webcast
6. Executive Changes at Ampio
7. Ampio Pharmaceuticals Schedules Webcast to Update Shareholders
8. Ampio Pharmaceuticals Announces Registered Direct Common Stock Offering of Approximately $9.436 Million
9. Ampio Responds to Recent Publications by Anonymous Short Sellers
10. Champions Oncology Reports Fiscal 2012 Second Quarter Financial Results
11. FDA Advisory Panel Recommends Against Approval of Champion® Heart Failure Management System for Patients With Heart Failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 29, 2014 The Competitive Intelligence (CI) function ... changes. CI leaders who adjust will succeed, and those ... new Best Practices, LLC study CI leaders from 32 ... - Use secondary research whenever possible - ... - Internal staff who are creative thinkers provide ...
(Date:8/29/2014)... Aug. 29, 2014 Pomerantz LLP has filed ... the "Company") (NASDAQ: EDAP ) and certain ... States District Court, Southern District of New ... behalf of a class consisting of all persons or ... and July 30, 2014, inclusive (the "Class Period"). This class ...
(Date:8/29/2014)... Aug. 29, 2014   Mast Therapeutics, Inc. ... announced today that Santosh Vetticaden, Chief Medical Officer ... Company, for personal reasons, in mid-September.  Edwin ... of Aires Pharmaceuticals, which Mast acquired earlier this ... the Company,s interim Chief Medical Officer.  Dr. Parsley ...
Breaking Medicine Technology:Using the Competitive Intelligence Function to Drive Better Business Decisions in the Pharmaceutical Sector 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A. and Certain Officers - EDAP 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A. and Certain Officers - EDAP 3Mast Therapeutics Announces Management Change 2Mast Therapeutics Announces Management Change 3Mast Therapeutics Announces Management Change 4
... Md., Jan. 31, 2011 Vanda Pharmaceuticals Inc. (Vanda) ... on the development and commercialization of products for central ... a universal shelf registration statement on Form S-3 with ... effective by the SEC, the shelf registration statement will ...
... Technologies, Inc. (the "Company") (Nasdaq: CMED ), ... announced that it will report its unaudited financial results ... before the U.S. market opens on February 18, 2011. ... 2011. The Company,s senior management will ...
Cached Medicine Technology:Vanda Pharmaceuticals Files Shelf Registration Statement 2Vanda Pharmaceuticals Files Shelf Registration Statement 3Vanda Pharmaceuticals Files Shelf Registration Statement 4China Medical Technologies to Announce Results for the Third Fiscal Quarter Ended December 31, 2010 on February 18, 2011 2
(Date:8/30/2014)... New York, NY (PRWEB) August 30, 2014 ... headlines will quickly ensue, as happened on Wednesday, August 27th, ... a successful attack on JPMorgan Chase & Co and ... that the FBI is actually investigating attacks on seven ... and how they may be affected, and the buzz quickly ...
(Date:8/30/2014)... As 500 Zoloft lawsuits pending ligation contend the SSRI andidepressant ... & Schulte LLC recently learned of a remand issued by ... in the Zoloft lawsuits was granted to 25 plaintiffs ... one SSRI lawsuit filed jointly under MDL 2342 ... sent back to the Missouri state court in which it ...
(Date:8/30/2014)... 30, 2014 Barton Associates, an industry ... tenens company , announces a new office location in ... Associates is headquartered in Peabody, MA, with additional staffing ... TX; and Jupiter, FL. , Barton Associates made the ... physician shortage crisis affecting the United States, a crisis ...
(Date:8/30/2014)... Spain Saturday 30 August 2014: The first ... patients with acute coronary syndromes (ACS) are published ... position paper was written jointly by the European ... Association (ACCA) and the European Association of Percutaneous ... , Professor Bulent Gorenek (Turkey), chairperson of the ...
(Date:8/30/2014)... Spain Saturday 30 August 2014: A new ... (HCM) identifies candidates for implantable cardioverter defibrillators (ICDs) ... at ESC Congress by Task Force Chairperson Professor ... on Diagnosis and Management of Hypertrophic Cardiomyopathy" are ... Journal (1) and on the ESC Website. ...
Breaking Medicine News(10 mins):Health News:Big Name Bank Hacks Highlight the Importance of Regular Testing and Effective Emergency Response 2Health News:Big Name Bank Hacks Highlight the Importance of Regular Testing and Effective Emergency Response 3Health News:Big Name Bank Hacks Highlight the Importance of Regular Testing and Effective Emergency Response 4Health News:Big Name Bank Hacks Highlight the Importance of Regular Testing and Effective Emergency Response 5Health News:Group of Plaintiffs in Zoloft Lawsuit Alleging SSRI Caused Birth Defect Are Granted Remand 2Health News:Group of Plaintiffs in Zoloft Lawsuit Alleging SSRI Caused Birth Defect Are Granted Remand 3Health News:Group of Plaintiffs in Zoloft Lawsuit Alleging SSRI Caused Birth Defect Are Granted Remand 4Health News:Group of Plaintiffs in Zoloft Lawsuit Alleging SSRI Caused Birth Defect Are Granted Remand 5Health News:Barton Associates to Open a New Office Location in Keene, NH 2Health News:First multidisciplinary recommendations on management of arrhythmias in ACS patients 2Health News:Sudden death predictor identifies ICD candidates in new ESC Guidelines 2
... ... to help anyone seeking improved health and wellness. Learn how to improve the look and ... enhance your physical appearance with information provided on this new Web site. , ... (PRWEB) June 17, 2010 -- A new Web site has ...
... , ... to announce the addition of Lázaro Garza as an Engineered Sales Representative for Ellsworth Adhesives ... ... announce the addition of Lázaro Garza as an Engineered Sales Representative for Ellsworth Adhesives S. ...
... Italy, Thursday 17 June 2010: Smoking cigarettes is a ... may have a negative impact on the effectiveness of ... these treatments, according to results of two studies presented ... European League Against Rheumatism in Rome, Italy. A further ...
... ... in 2010 Focusing on Professional, Olympic, and Recreational Athletes , ... Washington, D.C. (PRWEB) June 17, 2010 -- Athletes for Hope ... Agassi, Muhammad Ali, and Lance Armstrong for the purpose of inspiring all athletes to engage ...
... ... Receives Seal of Approval from Industry Voice , ... Fishkill, NY (PRWEB) June 17, 2010 -- Dear ... dentistry and oral health, has announced that the International Congress of Oral Implantologists ...
... ... released Semantics Platform v 2.0 which is made up of three products: Semantics.Datacenter, Semantics.Server, ... product offerings in industry standard benchmark tests (Berlin 100M 5/25/10). , ... Brattleboro, VT (PRWEB) June ...
Cached Medicine News:Health News:New Web Site Provides Helpful Exercise and Nutrition Tips 2Health News:Ellsworth Adhesives Announces New International Engineered Sales Representative 2Health News:Smoking cigarettes is a predictor of RA and may negatively impact on efficacy of anti-TNFs 2Health News:Smoking cigarettes is a predictor of RA and may negatively impact on efficacy of anti-TNFs 3Health News:Athletes for Hope Awarded $2 Million Grant by Kellogg Foundation 2Health News:Athletes for Hope Awarded $2 Million Grant by Kellogg Foundation 3Health News:International Congress of Oral Implantologists (ICOI) Joins Other Professional Organizations Endorsing Dear Doctor Magazine 2Health News:Intellidimension Releases New Version of Semantic Web Technologies 2
... a combination of innovative design, consistently reliable ... I-125 implant an ideal choice for your ... every BrachySource I-125 implant order is backed ... required by clinicians who must meet the ...
... BrachySource iodine-125 implant is a combination of ... visibility that makes BrachySource I-125 implant an ... can be confident that every BrachySource I-125 ... management services which is required by clinicians ...
The silicone Tractfinder provides excellent fluoroscopic visualization. Manipulation of the movable core guidewire flexes the tapered proximal tip for maximum control in negotiating a tortuous ureter...
... Used for temporary internal drainage from the ... of a stricture. The segment with no ... lumen while preventing ingrowth of the ureteral ... peel-open packages. Intended for one-time use. CAUTION: ...
Medicine Products: